top of page
PAPO LAB
NANOBODY ENGINEERING
We develop and characterize nanobodies that present tight and specific binding and internalization into PSMA or RTK positive cells and that accumulate specifically in PSMA or RTK positive tumors. We then conjugate these nanobodies to cytotoxic drugs, and we show that the conjugate internalizes specifically into PSMA or RTK positive cells, where the drug is released and induces cytotoxic activity both in cells and in preclinical models of cancer.
Related publications
Structural analysis of nanobody interactions with their prostate-specific membrane antigen binding epitopes
Alon-Zchut G, Zalk R, Huynh T T, Zalutsky M. R, Weizmann Y, Zarivach R, & Papo, N. International Journal of Biological Macromolecules, 2025.
Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy
Tzuri, N., Yegodayev, K. M., Elkabets, M., Aharoni, A., & Papo, N. Scientific Reports. 2023.
In vitro inhibition of cancer angiogenesis and migration by a nanobody that targets the orphan receptor Tie1
Meltzer M, Eliash N, Azoulay Z, Hadad U, Papo N. Cellular and Molecular Life Sciences. 2022.
Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.
Rosenfeld L, Sananes A, Zur Y, Cohen S, Dhara K, Gelkop S, Ben Zeev E, Shahar A, Lobel L, Akabayov B, Arbely E, Papo N. J Med Chem. 2020.
bottom of page